Study summary

Bexicaserin cut motor seizures by about 60% in severe childhood-onset epilepsies

PACIFIC trial (bexicaserin) · 52 people, phase 1b/2a · Published February 2026, Epilepsia

59.8%median drop in motor seizures, vs 17.4% with placebo

What was tested

Bexicaserin, a pill that activates the 5-HT2C serotonin receptor, or placebo in teens and adults with developmental and epileptic encephalopathies (DEEs) such as Dravet and Lennox-Gastaut syndromes.

What they found

What it means

Now in a phase 3 trial (DEEp SEA) whose main analysis was due October 2026.

Epilepsia, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.